The Future for HER2-Directed ADCs

The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.

The FDA approved selpercatinib for RET fusion–positive advanced solid tumors.

Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.

A triplet combination regimen led to high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm.

The CDH17-targeting antibody-drug conjugate received the designation for previously treated advanced unresectable or metastatic colorectal cancer.

Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.

The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.

Ruxolitinib plus extracorporeal photopheresis drove responses in steroid-refractory or -dependent chronic graft-vs-host disease.